Cargando…
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval of a clinical trial application for Phase I clinical studies of ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The study design, route of administ...
Autores principales: | Kuryk, Lukasz, Vassilev, Lotta, Ranki, Tuuli, Hemminki, Akseli, Karioja-Kallio, Aila, Levälampi, Onerva, Vuolanto, Antti, Cerullo, Vincenzo, Pesonen, Sari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552138/ https://www.ncbi.nlm.nih.gov/pubmed/28796812 http://dx.doi.org/10.1371/journal.pone.0182715 |
Ejemplares similares
-
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks
por: Kuryk, Lukasz, et al.
Publicado: (2019) -
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
por: Kuryk, Lukasz, et al.
Publicado: (2018) -
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients
por: Majumder, Mamun, et al.
Publicado: (2014) -
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
por: Ranki, Tuuli, et al.
Publicado: (2016) -
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
por: Pesonen, Sari, et al.
Publicado: (2015)